Aclaris Therapeutics, Inc. · NASDAQ:ACRS

Aclaris Therapeutics — Technical Presentation (December 2018)

30 slides from Aclaris Therapeutics's technical presentation, Dec 17, 2018

  1. Slide 1: R&D Update: ATI-502 and ATI-501 in Alopecia Areata and Vitiligo

    R&D Update ATI-502 Topical JAK 1/3 Inhibitor Alopecia Areata Vitiligo ATI-501 Oral JAK 1/3 Inhibitor Alopecia Areata 1 December 17, 2018 Exhibit 99.2

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by w

  3. Slide 3: Important steps in defining the therapeutic regimen

    • Positive proof of principle of the use of a topical JAK 1/3 to treat: – Alopecia areata (AA) – Vitiligo • Provide insight into the emotional burden of AA and vitiligo • Elucidate the potential role of topical therapy in patients with patchy AA, alopecia totalis (AT) and alopecia universalis (AU) –

  4. Slide 4: Alopecia Areata – 1.8% of the US Population

    Alopecia Areata – 1.8% of the US Population 4 4 5.8M Alopecia Areata Cases in the US Highest frequency areas highlighted COMMON BODY LOCATIONS SYMPTOM FREQUENCY Always 32% At least once per month 18% Every few months 20% At least once per year 12% Less than once per year 6% First occurrence 12% 72%

  5. Slide 5: AUATB-201 Topical Australian Eyebrow Study

    AUATB-201 Topical Australian Eyebrow Study

  6. Slide 6: AUATB-201 Topical eyebrow study

    • An ongoing Phase 2 open-label clinical trial of ATI-502, a topical JAK 1/3 inhibitor, for the treatment of AA in Australia. • In this trial, Aclaris is evaluating the safety and efficacy of ATI-502 on the regrowth of eyebrows in patients with AA, including patients with AT and AU. – 12 patients en

  7. Slide 7: Patient photos: baseline and ~6 months on study drug

    7 (~6 months on study drug) (Baseline)

  8. Slide 8: Patient photos: baseline and ~6 months on study drug

    8 (Baseline) (~6 months on study drug)

  9. Slide 9: Patient photos: baseline and ~6 months on study drug

    9 (Baseline) (~6months on study drug)

  10. Slide 10: Patient photos: baseline and ~6 months on study drug

    10 (Baseline) (~6 months on study drug)

  11. Slide 11: AA-202 Topical 28-Day PK/PD Study with 12-Month Open Label Extension

    AA-202 Topical 28 Day PK/PD Study with 12-Month Open Label Extension

  12. Slide 12: AA-202 Topical PK/PD study results

    • An ongoing Phase 2 clinical trial of ATI-502, a topical JAK 1/3 inhibitor, for the treatment of AT/AU. • After completing the 28-day portion of the trial, patients entered a -month open-label extension during which all continuing patients received drug. – 11 patients enrolled with the most severe

  13. Slide 13: Patient photos: baseline and ~6 months on study drug

    1313 (Baseline) (~6 months on study drug)

  14. Slide 14: Patient photos: baseline and ~6 months on study drug

    14 (Baseline) (~6 months on study drug) 14

  15. Slide 15: Patient photos: baseline and ~6 months on study drug

    1515 (Baseline) (~6 months on study drug) 15

  16. Slide 16: Phenotypic Spectrum

    Phenotypic Spectrum 16

  17. Slide 17: Baseline SALT 100%

    = Baseline SALT 100% ~ (aclaris. | » THERAPEUTICS

  18. Slide 18: Baseline SALT 51%

    Baseline SALT 51% 18

  19. Slide 19: Baseline SALT 43%

    Baseline SALT 43% 19

  20. Slide 20: Baseline SALT 34%

    Baseline SALT 34% 20

  21. Slide 21: Baseline SALT 24%

    = Baseline SALT 24% ~~ {aclaris. a

  22. Slide 22: Spectrum of Hair Loss

    Spectrum of Hair Loss 22 24% 43%34% 51% 100%

  23. Slide 23: Current treatment paradigm

    Current treatment paradigm 23 https://www.naaf.org/alopecia-areata/alopecia-areata-treatments - Last accessed 12-14-18

  24. Slide 24: Alopecia Areata: Potential Treatment Paradigms

    Topical Treatments Systemic Treatments Oral JAK inhibitor Adult / Pediatric Patchy AA Adult AT/AU patients Alopecia Areata: Potential Treatment Paradigms 24 Topical JAK inhibitor Pediatric AT/AU patients Increasing Disease Severity INDUCTION: Topical JAK inhibitor may be efficacious in patients with

  25. Slide 25: VITI-201 Topical 6-month Open Label Study in Non-Segmental Facial Vitiligo

    VITI-201 Topical 6-month Open Label Study in Subjects with Non-Segmental Facial Vitiligo

  26. Slide 26: Vitiligo - 3.3% of US Population

    Vitiligo - 3.3% of US Population 26 10.9M • Slightly higher incidence in the West (26%) • Greater proportion with HH incomes of $35K to under $100K (53%) • Above-average percentage of Afro-Americans with condition (32%) and fewer White, Non- Hispanic (43%) Vitiligo Cases in the US Highest frequency

  27. Slide 27: Patient photos: baseline and ~4 months on study drug

    27 (Baseline) (~4 months on study drug)

  28. Slide 28: Patient photos: baseline and ~4 months on study drug

    28 (Baseline) (~4 months on study drug)

  29. Slide 29: Patient photos: baseline and ~4 months on study drug

    29 (~4 months on study drug) (Baseline)

  30. Slide 30: Summary and next steps

    • Alopecia areata – Established proof of principle for topical JAK inhibitor as a potential treatment – Topical JAK inhibitor could have role as first line therapy for patchy disease, second line maintenance therapy, or adjunctive treatment for more severe disease – Clinical response of topical JAK

Aclaris Therapeutics — Technical Presentation (December 2018) on 6ix